These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 25085765)

  • 1. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer.
    Hung JJ; Jeng WJ; Hsu WH; Chou TY; Huang BS; Wu YC
    J Thorac Oncol; 2012 Jul; 7(7):1115-23. PubMed ID: 22592210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
    Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
    Hasselle MD; Haraf DJ; Rusthoven KE; Golden DW; Salgia R; Villaflor VM; Shah N; Hoffman PC; Chmura SJ; Connell PP; Vokes EE; Weichselbaum RR; Salama JK
    J Thorac Oncol; 2012 Feb; 7(2):376-81. PubMed ID: 22198429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm.
    Latifi K; Oliver J; Baker R; Dilling TJ; Stevens CW; Kim J; Yue B; Demarco M; Zhang GG; Moros EG; Feygelman V
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1108-13. PubMed ID: 24529716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
    Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
    Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
    Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N
    Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
    De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
    J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
    Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastasis dynamics for non-small-cell lung cancer: effect of patient and tumor-related factors.
    Kelsey CR; Fornili M; Ambrogi F; Higgins K; Boyd JA; Biganzoli E; Demicheli R
    Clin Lung Cancer; 2013 Jul; 14(4):425-32. PubMed ID: 23499299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
    Parker SM; Siochi RA; Wen S; Mattes MD
    Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer.
    Varlotto JM; Recht A; Nikolov M; Flickinger JC; Decamp MM
    Cancer; 2009 Feb; 115(4):851-8. PubMed ID: 19140203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.
    Higgins KA; Chino JP; Ready N; D'Amico TA; Berry MF; Sporn T; Boyd J; Kelsey CR
    J Thorac Oncol; 2012 Jul; 7(7):1141-7. PubMed ID: 22617241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.